An evaluation of the FDA adverse event reporting system and the potential for reporting bias

被引:5
|
作者
Monnot, Andrew D. [1 ]
Fung, Ernest S. [2 ]
Compoginis, Goli S. [3 ]
Towle, Kevin M. [1 ]
机构
[1] Cardno ChemRisk, 235 Pine St,Suite 2300, San Francisco, CA 94104 USA
[2] Cardno ChemRisk, Aliso Viejo, CA USA
[3] Univ Southern Calif, Keck Sch Med, Dept Dermatol, Los Angeles, CA 90007 USA
关键词
adverse event reporting; cosmetics; news media;
D O I
10.1111/jocd.14065
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background The FDA maintains the Adverse Event Reporting System (CAERS) database, which contains product complaint reports for foods, dietary supplements, and cosmetics. Product line perception and subsequent adverse event reporting may be impacted by negative media attention. Methods The purpose of this analysis was to use the CAERS database to analyze temporal trends in adverse event reporting before and after media coverage of alleged health effects, using WEN by Chaz Dean (WCD) cleansing conditioners as a case study. WCD cleansing conditioner adverse event reports from January 2005 to December 2018 were abstracted from the CAERS database. Zero-inflated negative binomial regression models were used to analyze the rate of adverse events (WCD events/10,000 WCD cleansing conditioner units sold/month), adjusted for temporal trends in CAERS. Results There was a statistically significant higher rate of adverse event reporting after negative media coverage in December 2015 (IRR 16.71 [95% CI: 7.89-35.39]) when compared to the rate of adverse event reporting before December 2015. Conclusions This analysis highlights the importance of assessing potential external factors, such as negative news media coverage, that may alter reporting behaviors due to societal shifts in product-specific risk perception. Consideration of these factors in post-market surveillance programs would result in more comprehensive safety evaluations.
引用
收藏
页码:1849 / 1854
页数:6
相关论文
共 50 条
  • [31] Evaluation of spontaneous adverse event reports for alopecia attributed to erenumab within the FDA adverse events reporting system
    Mekkawy, Mohamed
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 478 - 478
  • [32] Introduction of a Mobile Adverse Event Reporting System Is Associated With Participation in Adverse Event Reporting
    Rubin, Daniel S.
    Pesyna, Colin
    Jakubczyk, Sharon
    Liao, Chuanhong
    Tung, Avery
    [J]. AMERICAN JOURNAL OF MEDICAL QUALITY, 2019, 34 (01) : 30 - 35
  • [33] Missing data in FDA adverse event reporting systems
    Smith, Sheila Weiss
    Gogolak, Victor V.
    Deshpande, Gaurav
    Chung, Stephanie
    Mehta, Shekhar H.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S72 - S72
  • [34] EXISTENCE OF NOTORIETY BIAS IN FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) DATABASE AND ITS IMPACT ON SIGNAL STRENGTH
    Reddy, Ravindra N.
    Viswam, K. S.
    Thomas, B. E.
    Nair, G.
    Maheswari, E.
    Swaroop, A. M.
    [J]. VALUE IN HEALTH, 2019, 22 : S763 - S763
  • [35] Commentary on 'Indoor tanning injuries: an evaluation of FDA adverse event reporting data'
    Feldman, Steven R.
    Fleischer, Alan B.
    [J]. PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE, 2009, 25 (04) : 221 - 222
  • [36] Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS)
    Woods, Richard H.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (08) : 2386 - 2395
  • [37] Analysis of tolerance to antidepressant drug treatment in FDA Adverse Event Reporting System
    Carnovale, Carla
    Gentili, Marta
    Vigano, Caterina
    Carnaghi, Giulia
    Beltrami, Marta
    Bosi, Monica
    [J]. PHARMACOLOGICAL RESEARCH, 2019, 141 : 616 - 617
  • [38] Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system
    Yibei Zhao
    Huiming Jiang
    Lifen Xue
    Mi Zhou
    Xiaobing Zhao
    Fei Liu
    SongJiang Jiang
    Jing Huang
    Long Meng
    [J]. International Journal of Clinical Pharmacy, 2024, 46 : 480 - 487
  • [39] An Experimental Investigation of Masking in the US FDA Adverse Event Reporting System Database
    Wang, Hsin-wei
    Hochberg, Alan M.
    Pearson, Ronald K.
    Hauben, Manfred
    [J]. DRUG SAFETY, 2010, 33 (12) : 1117 - 1133
  • [40] Pharmacovigilance Analysis Of FDA Adverse Event Reporting System (FAERS) Events For Inclisiran
    Rajak, Kripa
    Halder, Anupam
    Gautam, Seema Sharma
    Khanal, Resha
    Atrash, Anas
    Goswami, Rohan
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43